PAL Equatorial Palm Oil Plc

RNS No 9026r
PALL CORPORATION
7th October 1997

HemaSure Found to Infringe Pall Patent 
 
Health/Medical Editors
 
           EAST HILLS, N.Y.--(BW HealthWire)--Oct. 7, 1997--Judge Thomas 
C. Platt, of the United States District Court for the Eastern 
District of New York, has issued an order holding that HemaSure's 
Leukonet(TM) leukocyte removal blood filter literally infringes Pall 
Corporation's (NYSE: PLL) U.S. Patent number 5,451,321.  

           In a 21 page Memorandum and Order, the judge granted Pall's 
motion for summary judgment on the issue of infringement of a patent 
relating to the venting system of blood filters.  

           Pall brought the case against HemaSure in 1996.  It contends that
HemaSure's infringement was willful and will ask for punitive 
damages.  In addition, in a separate lawsuit, Pall has charged 
HemaSure with infringement of two other Pall patents.  

           Pall will now request that the court enter a preliminary 
injunction against HemaSure's further manufacture, use or sale of the
infringing products.  

           Pall Corporation, with annual sales over $1 billion, is based in 
East Hills, New York, USA.  The Company has the broadest based 
filtration and separation capabilities in the world.  Since 1946, 
Pall Corporation has demonstrated technological leadership and 
offered innovative solutions to complex fluid clarification and 
purification problems in each of its three major markets: Health 
Care, Aeropower and Fluid Processing.  The Company employs 8,500 
people at offices and manufacturing facilities throughout the world.
The Company's shares are listed on the New York Stock Exchange (PLL) 
and the London Stock Exchange (0668260).  
     
    CONTACT:  Jeremy Hayward-Surry
              (516) 484-5400

END

MSCUBGCGUBGMPWM

Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jul 2024 to Aug 2024

Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Aug 2023 to Aug 2024